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Although it is well established that recurrent hypoglyce-
mia leads to hypoglycemia unawareness, the mecha-
nisms responsible for this are unknown. One hypothesis
is that recurrent hypoglycemia alters brain glucose trans-
port or metabolism. We measured steady-state brain
glucose concentrations during a glucose clamp to deter-
mine whether subjects with type 1 diabetes and hypo-
glycemia unawareness may have altered cerebral glu-
cose transport or metabolism after exposure to recurrent
hypoglycemia. We compared 14 subjects with diabetes
and hypoglycemia unawareness to 27 healthy control
subjects. Brain glucose concentrations were measured
under similar metabolic conditions using in vivo 1H nu-
clear magnetic resonance (NMR) spectroscopy at 4 Tesla
during a hyperglycemic clamp (plasma glucose 
16.7 mmol/l) with somatostatin and insulin. Subjects with
type 1 diabetes and hypoglycemia unawareness had
signiﬁcantly higher brain glucose concentrations com-
pared to that in controls under the same conditions
(5.5  0.3 vs. 4.7  0.1 mol/g wet weight, P  0.016).
These data suggest that changes in brain glucose trans-
port or metabolism may occur as a result of recurrent
hypoglycemia. © 2004 Wiley-Liss, Inc.
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Hypoglycemia remains the limiting factor for achieving
normal glycemic control in patients with type 1 diabetes
(Cryer, 1994). The ﬁndings of the Diabetes Control and
Complications Trial (DCCT) established that improved glu-
cose control signiﬁcantly reduces the rate at which diabetes-
related complications occur in subjects with type 1 diabetes
(DCCT Research Group, 1993). It also determined, how-
ever, that patients with type 1 diabetes and hemoglobin A1c
values less than 7.5% experience hypoglycemia three times
more often than do those with poor control (DCCT Re-
search Group, 1993). The fear associated with an increased
frequency of hypoglycemia is a major barrier in intensifying
insulin management for the purpose of preventing the long-
term complications of diabetes.
Recurrent hypoglycemia frequently leads to the
condition of hypoglycemia unawareness in which a patient
is no longer able to perceive symptoms of hypoglycemia
and consequently is unable to take action to prevent the
development of severe hypoglycemia. In these cases, the
autonomic symptoms of hypoglycemia (tachycardia, ner-
vousness, and tremor) are not recognized or do not occur
before development of neuroglycopenia. Intensively
treated patients with type 1 diabetes require a lower glu-
cose level to elicit a counterregulatory response than do
more poorly controlled patients (Amiel et al., 1988;
Dagogo-Jack et al., 1993; Cryer, 1994). The mechanism
underlying this condition, which has been termed
hypoglycemia-associated autonomic failure (HAAF), is
unclear but may involve a compensatory increase in cere-
bral glucose transport rate so that sufﬁcient glucose is
provided to the brain for its energy needs even in the face
of systemic hypoglycemia (Boyle et al., 1994).
Traditional thinking is that a continuous supply of
glucose is necessary for normal brain function with the
brain being unable to store more than a few minutes worth
of glucose for use during hypoglycemia (Pardridge, 1983).
Glucose reaches the central nervous system (CNS) by
crossing the blood–brain barrier via the speciﬁc transport
protein, GLUT1 (Pardridge et al., 1990). When exposed
to hypoglycemia, transcription and translation (Boado and
Pardridge 1993) of endothelial GLUT1 at the blood–brain
barrier are increased. Chronic and prolonged hypoglyce-
mia in rodents increased the number of glucose transport-
ers in the brain (Koranyi et al., 1991), resulting in in-
creased movement of glucose (McCall et al., 1982). In
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patients with frequent hypoglycemia and near normal
values of hemoglobin A1c (7.2  0.5%), brain glucose
uptake in the face of systemic hypoglycemia is unchanged
from euglycemia, whereas patients with poorly controlled
diabetes and healthy controls have reduced brain glucose
uptake during systemic hypoglycemia (Boyle et al., 1995).
These observations suggest that brain glucose uptake may
be increased in response to recurrent hypoglycemia in
patients with well-controlled diabetes, therefore causing
an increase in brain glucose concentration to ensure an
adequate delivery of substrate during subsequent episodes
of hypoglycemia. This compensatory increase in brain
glucose concentration may be partly responsible for the
inability to detect symptoms of hypoglycemia in patients
with hypoglycemia unawareness. Studies with positron
emission tomography (PET) have been unable to support
this hypothesis, although none were sufﬁciently powered
to identify metabolic differences that were smaller than
20% (Segel et al., 2001).
Although other methods have been used to examine
brain glucose metabolism, proton magnetic resonance
(MR) spectroscopy is currently the only method that
allows quantiﬁcation of in vivo native glucose concentra-
tions. With current methodology, sufﬁcient signal-to-
noise to permit good resolution of the glucose signal and
accurate quantiﬁcation of brain glucose concentrations is
obtained only under hyperglycemic conditions (Gruetter,
1996). We have demonstrated previously that a linear
relationship exists between plasma and brain glucose con-
centrations with plasma glucose values ranging from 4.4–
24.5 mmol/l in humans (Seaquist et al., 2001). Similar
observations have been made by Choi et al. (2001) in
animals with plasma glucose values ranging from 0.2–
30 mmol/l. We can therefore anticipate that differences in
brain glucose concentrations detected during hyperglyce-
mia would also exist during hypoglycemia.
To determine whether recurrent hypoglycemia in
patients with type 1 diabetes results in small but presum-
ably clinically relevant changes in brain glucose metabo-
lism, we measured steady-state brain glucose concentra-
tions under controlled metabolic conditions using high-
ﬁeld 1H MR spectroscopy. We hypothesized that subjects
with hypoglycemia unawareness would have higher brain
glucose concentrations than control subjects would under
these conditions and that our observations would provide
insights into the effect of recurrent hypoglycemia on brain
glucose transport and metabolism.
MATERIALS AND METHODS
Study Participants
Subjects with intensively treated type 1 diabetes of greater
than 5 years duration were recruited from the Endocrine Clinics
at the University of Minnesota. To be included, subjects were
required to be18 years of age, have a hemoglobin A1c7.5%
at the time of recruitment (normal subject range was 4.5–6.0%),
experience a minimum of two self-reported episodes of hypo-
glycemia per week, and have hypoglycemia unawareness veri-
ﬁed by the questionnaire developed by Clarke et al. (1995). This
questionnaire consists of eight questions about the frequency
and severity of asymptomatic hypoglycemia (deﬁned as home
glucose readings 70 mg/dl) and severe hypoglycemia (deﬁned
as episodes in which the subjects was unconscious or had a
seizure and needed glucagon or intravenous glucose for recov-
ery), and has been validated as a reliable method to identify
subjects with type 1 diabetes and hypoglycemia unawareness
(Clarke et al., 1995). In addition to these criteria, subjects also
met the requirements for the MR study, which excludes subjects
weighing more than 300 pounds. Control subjects were re-
cruited from the Fairview-University Medical Center and Uni-
versity of Minnesota communities and were similar to the sub-
jects with type 1 diabetes and hypoglycemia unawareness with
respect to body mass index and gender. The study protocol was
conducted according to procedures approved by the Institu-
tional Review Board at the University of Minnesota.
Protocol
Subjects with type 1 diabetes were asked to monitor and
record their blood glucose values before bedtime and at each
meal during the week before the study. The subjects with type
1 diabetes were admitted to the General Clinical Research
Center at the University of Minnesota the night before the
experiment. Their evening dose of long-acting insulin was with-
held and they were maintained on an intravenous infusion of
insulin overnight (approximately 8–10 hr) to maintain their
blood glucose between 5.6–10.0 mmol/l (100–180 mg/dl). At
7:30 AM the following morning, the insulin infusion was dis-
continued and subjects were transported to the Center for
Magnetic Resonance Research for the experiment.
All subjects were studied in the morning at the Center for
Magnetic Resonance Research after an overnight fast. In prepara-
tion for the experiment, an intravenous catheter was placed in each
in each antecubital region for the delivery of glucose, insulin,
potassium, and somatostatin. A third intravenous catheter was
placed retrograde in the foot for blood sampling. This leg was
wrapped in heated towels and hot packs to arterialize the venous
blood (Seaquist, 1997). At baseline, samples were obtained for
glucose, insulin, and ketones. The somatostatin infusion was begun
and advanced to a rate of 0.16 g/kg/min over 30–45 min to
suppress endogenous insulin secretion (Yen et al., 1974). An intra-
venous insulin infusion (0.5 mU/kg/min, Humulin Regular; Eli
Lilly and Company) was started in conjunction with the somatosta-
tin at time zero. During the ﬁrst 30–45 min, basal euglycemia was
maintained by infusing glucose (50% dextrose) at a variable rate
while the somatostatin infusion was increased. Thereafter, the glu-
cose infusion was increased rapidly to clamp the plasma glucose
concentration at 16.7 mmol/l; a level sufﬁciently elevated to yield
a robust signal of the H-1 proton of the -glucose at 5.23 ppm in
spectra acquired from the human brain. Spectroscopic measure-
ments were begun after subjects had been at stable hyperglycemia
for a minimum of 20 min. The study design is depicted in Figure 1.
MR Spectroscopy
Experiments were carried out on a 4-Tesla Siemens/
Oxford magnet interfaced to a Varian console as described
previously (Gruetter et al., 1998a,b). Subjects were placed su-
pine on a bed above the surface coil and their heads were held
in place by cushions. To decrease the exposure to gradient noise,
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all subjects wore earplugs. A quadrature transmit/receive half-
volume radio frequency (RF) coil was used (Adriany and Gru-
etter, 1997). A 16-ml volume of brain in the occipital cortex was
identiﬁed for data acquisition. Selection of the volume of inter-
est (VOI) for the spectroscopy was based on anatomic landmarks
identiﬁed on T2-weighted rapid acquisition with relaxation
enhancement (RARE) multislice magnetic resonance imaging
(MRI; Lee et al., 1995). In vivo 1H MR spectra were measured
using short echo-time stimulated echo acquisition mode
(STEAM) (echo time [TE]  4 msec; repetition time [TR] 
4.5 sec) combined with outer volume suppression and variable
power and optimized relaxation delays (VAPOR) water sup-
pression (Tkac et al., 1999). The spectra from the VOI were
measured in an interleaved manner. Localized shimming was
carried out using FASTMAP (Gruetter, 1993; Gruetter and
Tkac, 2000), which has resulted in consistent linewidths for the
water resonance of 7–9 Hz. Data were averaged over a period of
1.2 min (blocks of 16 scans), which were stored separately in
memory. This allowed elimination of small frequency drifts
between spectra before summation on the order of a few hertz
and averaged over at least 10 min. In each case, the plasma
glucose concentration was maintained at steady state for at least
20 min before spectral data were acquired. Data from the VOI
was acquired over a minimum period of 25 min during which
glycemia was clamped at the target level.
Nuclear MR Spectral Analysis
Free induction decays were zero ﬁlled and apodized with
exponential multiplication (2 Hz line broadening). An example
of the spectra acquired is shown in Figure 2. Peak area of the
glucose (at 5.23 ppm), creatine (3.03 ppm), and macromolecule
(2.98 ppm) resonances were quantiﬁed using peak-ﬁtting soft-
ware supplied by the spectrometer manufacturer, as described
previously (Gruetter et al., 1996, 1998a). The area under the
glucose peak at 5.23 ppm was calculated relative to the area
under the creatine methyl resonance at 3.04 ppm. The concen-
tration of creatine was set to 10 mol/g wet weight based on
cortical concentrations of 9.6 mol/g wet weight (Petroff et al.,
1989) and on contributions of 1 mol/g wet weight
-aminobutyric acid (GABA; Rothman et al., 1993) and
1–2 mol/g wet weight glutathione (GSH) in this region of the
brain (Choi et al., 2002; Terpstra et al., 2002).
Assessment of Hormonal Counterregulation
Subjects with type 1 diabetes and hypoglycemia unaware-
ness were asked to undergo an assessment of hormonal coun-
terregulation to hypoglycemia within 24 hr of completing the
magnet study. In this assessment, insulin was infused intrave-
nously at a rate of 2.0 mU/kg/min and blood glucose was
allowed to fall to 2.7 mmol/l, where it was maintained for
30 min. Samples for the immediate measurement of plasma
glucose were obtained every 5 min and glucose (20% dextrose)
was infused intravenously as necessary to maintain the glucose at
the target level. Samples for the subsequent measurement of
glucagon were collected at baseline and every 10 min during
hypoglycemia in iced tubes containing EDTA/Trasylol
(500 U/ml). Samples collected for subsequent measurement of
epinephrine and norepinephrine were collected using the same
schedule in chilled tubes containing 50 l of a solution of EGTA
(90 mg/ml) and GSH (60 mg/ml). Counterregulation was as-
sessed similarly in a group of control subjects for comparison.
Laboratory Analyses
During the study, blood samples were obtained every
5 min for determination of the blood glucose concentration
using an autoanalyzer (Beckman, Fullerton, CA). During the
magnet study, additional samples were taken every 30 min for
later determination of serum insulin concentrations by a Beck-
man Access instrument. Serum ketones were measured in the
clinical laboratory using a qualitative test based on a nitroferro-
cyanide reaction. Hemoglobin A1c was measured in the subjects
with type 1 diabetes by high-performance liquid chromatogra-
phy (HPLC; DCCT Research Group, 1987). Blood samples
obtained during the hypoglycemia study were assayed for glu-
cagon using a radioimmunoassay (Harris et al., 1979) and for
epinephrine and norepinephrine levels using a single isotope
radioenzymatic assay (Evans et al., 1978).
Statistical Analysis
All data are reported as mean standard error of the mean
(SEM). The hormonal response to hypoglycemia is reported as
the peak value achieved during the hypoglycemia period with
the basal value subtracted. The hypoglycemia unaware group
was compared to the control group with two-sample, two-sided
Student’s t-test, and after adjusting for plasma glucose with
analysis of covariance. All analyses were carried out with SAS
v8.2 (SAS Institute Inc., Cary, NC).
RESULTS
In total, 14 participants with type 1 diabetes and
hypoglycemia unawareness veriﬁed by clinical history and
Cox questionnaire and 27 healthy participants were stud-
ied. The two groups were similar with respect to body
mass index and gender (Table I), but the hypoglycemia
unaware group was on average 10 years older and there
was little overlap in ages (P  0.0065). No association
appeared between age and brain glucose concentration
(Spearman correlation  0.18, P  0.26), however,
among all subjects studied. The secretory response of
Fig. 1. Experimental protocol. Subjects were given intravenous infu-
sions of somatostatin and insulin starting at time zero. Glucose was then
infused as necessary to maintain plasma glucose at 16.7 mmol/l between
0–180 min. Data to measure cerebral glucose concentrations were
acquired by MR spectroscopy during the ﬁnal 60 min of the study.
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glucagon, epinephrine, and norepinephrine during hypo-
glycemia was signiﬁcantly lower in the subjects with type
1 diabetes and hypoglycemia unawareness as compared to
that in controls, although not all of the subjects with
hypoglycemia unawareness studied in the magnet protocol
agreed to undergo the hypoglycemic clamp study
(Table II). This blunted counterregulatory response was
apparent despite the lower plasma glucose levels achieved
in the hypoglycemia unaware group during the hypogly-
cemia clamp.
During the magnet experiment, the concentrations
of plasma glucose in the two groups were maintained
using the glucose/insulin clamp technique (Table III).
Serum ketone measurements were negative in all subjects
during the course of the experiment. Brain glucose con-
centrations were 17  6% higher in the hypoglycemia
unaware group than in the control group (P  0.016).
The brain glucose concentration in the hypoglycemia
unaware group remained signiﬁcantly higher than that in
controls after adjusting for the difference in plasma glucose
during the clamp (5.46  0.3 vs. 4.8  0.2; P  0.0367).
The brain-to-plasma glucose ratio was also higher in the
hypoglycemia unaware group (0.33  0.02 vs. 0.29 
0.01; P  0.0334).
DISCUSSION
We found that patients with type 1 diabetes and
hypoglycemia unawareness had higher brain glucose con-
centrations than healthy volunteers did when studied un-
der the same hyperglycemic conditions. Because steady-
state brain glucose concentration reﬂects the balance
between glucose entering the brain across the blood brain
barrier and glucose leaving the brain via metabolism, our
ﬁndings support the hypothesis that recurrent hypoglyce-
mia may increase cerebral glucose transport or decrease
cerebral glucose metabolism. These observations provide
evidence that the brain may compensate for chronic
changes in glycemia so as to ensure a constant supply of its
preferred energy substrate.
In evaluation of the difference observed, several factors
must be taken into consideration. First, the standard error of
the mean between the brain glucose concentrations measured
in the hypoglycemia unaware group is greater than that the
control group. Although all subjects were validated to have
hypoglycemia unawareness and those who agreed to partic-
ipate were shown to have a blunting of counterregulatory
hormones in response to hypoglycemia, differences in the
frequency of hypoglycemia and duration of hypoglycemia
among subjects may account for the variability. Careful eval-
uation of the data failed to provide sufﬁcient justiﬁcation to
omit any of the reported data points. We found no correla-
tion between number of hypoglycemia episodes reported
during the week before the experiment and brain glucose
concentration (data not shown). We interpret these data to
demonstrate that subjects with type 1 diabetes and hypogly-
cemia unawareness have a brain glucose concentration that is
higher than that in normal controls studied under the same
metabolic conditions. Although the difference may be nu-
merically small, the clinical importance of the difference may
be signiﬁcant. Under normal conditions, the plasma glucose
concentration is approximately four to ﬁve times higher than
is the brain glucose concentration. During hypoglycemia
(plasma glucose  2.5 mmol/l), a 10% increase in brain
glucose concentration (0.55 vs. 0.50 mol/g wet weight)
may be enough to have a clinical impact on the threshold for
neuroglycopenic symptoms.
Fig. 2. 1H MR spectra of a human brain
during glucose infusion. 1H MR spec-
troscopy at 4 Tesla was used to acquire a
spectrum of a 16-ml volume of occipital
cortex from a patient with diabetes
when plasma glucose was clamped at
16.7 mmol/l. The peak at 5.23 ppm was
used to quantify the brain glucose con-
centration. Glc, glucose; Cr, creatine;
Ins, inositol; Cho, choline; Glu, gluta-
mate; NAA, N-acetyl-aspartate.
TABLE I. Subject Characteristics*
Subject group Gender (M/F) BMI (kg/m2)
Hemoglobin
A1c (%)
Hypoglycemia unaware 11/3 26.7  1.0 6.9  0.2
Controls 17/10 26.7  1.0 NA
P 0.32 0.98 NA
*M, male; F, female; BMI, body mass index.
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In our study, the plasma glucose concentrations in
the patient group were on average slightly higher than
those the control group, although the difference was not
statistically signiﬁcant. With the linear relationship that
exists between plasma and brain glucose concentrations
(Gruetter et al., 1998a; Choi et al., 2001; de Graaf et al.,
2001; Seaquist et al., 2001), it is possible that this differ-
ence in plasma glucose concentration may have lead to an
artifactual increase in brain glucose concentration in pa-
tients with diabetes. After adjusting for this difference
statistically, however, the hypoglycemia unaware group
still experienced signiﬁcantly higher brain glucose concen-
tration in gray matter.
Subjects with diabetes also had a signiﬁcantly higher
insulin concentration during the clamp study than did the
controls although levels remained within the physiologic
range. The increased plasma insulin concentration in the
patient group may have been the result of subcutaneous
depots of long acting insulin or a decreased insulin clear-
ance. We have shown previously under the same experi-
mental conditions that insulin is without a signiﬁcant
effect on the kinetics of cerebral glucose transport and
metabolism in normal controls and that pharmacologic
concentrations of plasma insulin do not change brain glu-
cose concentrations (Seaquist et al., 2001). It is therefore
unlikely that the difference in plasma insulin concentra-
tions between the two groups can account for the differ-
ence in brain glucose concentration. PET studies have also
shown that brain glucose metabolism is not sensitive to
insulin concentration with the physiologic range (Cran-
ston et al., 1998; Hasselbach et al., 1999).
The effects of recurrent hypoglycemia and hypogly-
cemia unawareness on brain glucose metabolism and the
development of hypoglycemia-associated autonomic fail-
ure have been the subject of past investigation. Although
upregulation of GLUT1 (Kumagai et al., 1995) and in-
creased transporter concentration on the luminal surface of
the blood–brain barrier (Simpson et al., 1999) have been
demonstrated in animals with chronic hypoglycemia, these
types of studies are impossible to replicate in otherwise
healthy human beings. One alternative approach has been
to measure brain glucose uptake as a surrogate for mea-
sures of glucose transport and metabolism. Using this
methodology, Boyle et al. (1995) found that subjects with
type 1 diabetes in good control had no change in brain
glucose uptake in the face of systemic hypoglycemia,
whereas subjects with type 1 diabetes in less optimal con-
trol and normal controls had a decrease in brain glucose
uptake under the same condition of hypoglycemia. This
evidence supports the hypothesis of a physiologic mech-
anism by which the brain protects itself from neuroglyco-
penia by preserving uptake. Other investigators have used
PET imaging to measure the rate of blood-to-brain glu-
cose transport and found no difference in the transport rate
in healthy subjects after euglycemia compared to that in
healthy subjects studied after a period of hypoglycemia
(Segel et al., 2001). Similarly, McCrimmon et al. (2003),
using microdialysis to measure the glucose concentration
in the extracellular ﬂuid of the inferior colliculus in rats,
found that a prior exposure to recurrent hypoglycemia did
not lead to an increase in glucose concentration, inferring
that hypoglycemia did not cause an increase in blood–
brain barrier glucose transport. Both of these studies were
powered to detect a difference of greater than 20% and
consequently were not able to detect a difference as small
as the 16% noted in our study.
In summary, we found that patients with type 1
diabetes and hypoglycemia unawareness had an increased
brain glucose concentration compared to that in healthy
controls under similar levels of glycemia. This observation
supports the hypothesis that recurrent hypoglycemia may
alter cerebral glucose uptake or metabolism to preserve
brain function in the context of systemic hypoglycemia.
The exact mechanism by which the brain glucose con-
centration is increased in response to recurrent hypogly-
cemia and hypoglycemia unawareness remains unknown.
Future investigation will be required to deﬁne clearly how
this compensatory response occurs.
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